Skip to main content

Table 3 Comparison of treatment groups across clinical and radiologic outcomes in the interval between 3 and 15 months after treatment initiation using approaches to address confounding

From: Comparison of dimethyl fumarate and interferon outcomes in an MS cohort

Outcome

Regression adjustment for all confounding factors

OR (95%CI)

Regression adjustment for propensity score

OR (95%CI)

Inverse probability weighting

OR (95%CI)

Clinical relapse(s)

3.43 (1.55, 7.60)

2.84 (1.33, 6.06)

2.34 (0.86, 6.72)

New lesion on brain MRI

4.40 (2.04, 9.50)

4.30 (2.02, 9.14)

3.77 (1.67, 8.99)

New GD + lesion on brain MRI

2.32 (0.87, 6.21)

2.26 (0.84, 6.08)

2.03 (0.67, 5.91)

New T2 lesion on brain MRI

4.89 (2.21, 10.85)

4.98 (2.27, 10.91)

4.11 (1.79, 10.04)

Sustained disease progression

1.32 (0.39, 4.42)

1.09 (0.36, 3.32)

0.92 (0.28, 2.44)

No relapse, new MRI lesion or sustained progression (NEDA)

0.27 (0.14, 0.50)

0.30 (0.16, 0.56)

0.35 (0.15, 0.75)

  1. Legend: OR Odds Ratio, CI Confidence Interval, Gd + Gadolinium-enhancing, NEDA No Evidence of Disease Activity. Estimated OR and 95% CI provided for each of the outcomes for each of the three approaches. OR > 1 indicates higher probability of having an event on IFNb-1a compared to DMF